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Abstract
Background: Although asthma symptoms can be temporarily controlled, it is recommended to use effective low-risk,
non-drug strategies to constitute a significant advance in asthma management. Acupuncture has been traditionally
used to treat asthma; however, the evidence for the efficacy of this treatment is still lacking. Previous clinical trials of
acupuncture in treating asthma were limited by methodological defects; therefore, high-quality research is required.
Methods/Design: This trial is designed as a multi-center, randomized, double-blind, parallel-group controlled trial.
Patients with mild to moderate asthma will be randomly allocated to either a verum acupuncture plus as-needed
salbutamol aerosol and/or prednisone tablets group or a sham acupuncture plus as-needed salbutamol aerosol and/or
prednisone tablets group. Acupoints used in the verum acupuncture group are GV14 (Da Zhui), BL12 (Feng Men), BL13
(Fei Shu) and acupoints used in the sham acupuncture group are DU08 (Jin Suo), BL18 (Gan Shu), BL19 (Dan Shu). After a
baseline period of 1 week, the patients in both groups will receive verum/sham acupuncture once every other day with
a total of 20 treatment sessions in 6 weeks and a 3-month follow-up. The primary outcome will be measured by using
the asthma control test and the secondary outcomes will be measured by using the percentage of symptom-free days,
the average dosage of salbutamol aerosol and/or prednisone tablets, lung functions, daily asthma symptom scores,
asthma quality of life questionnaire, and so on.
Discussion: This trial will assess the effect of acupuncture on asthma and aims to provide reliable clinical evidence for
the efficacy of acupuncture in treating asthma.
Trial registration: ClinicalTrials.gov Identifier: NCT01931696, registered on 26 August 2013
Keywords: Acupuncture, Chronic asthma, Efficacy, RCT, Study protocol
Background
Asthma is a noninfectious chronic disease that affects as
many as 334 million people of all ages in all parts of the
world [1]. The World Health Organization (WHO) has
estimated that 15 million disability-adjusted life-years
are lost and 250,000 asthma deaths occur around the
world annually [2, 3]. Asthma is now recognized as a
disease of major public health importance due to its
constantly increasing prevalence, morbidity, and mortal-
ity in recent decades [2, 4].
Asthma is characterized by variable symptoms of wheeze,
shortness of breath, chest tightness and/or cough, and vari-
able expiratory airflow limitations [5]. Inhaled corticoste-
roids (ICS) are used as first line therapy for asthma [6];
however, a significant proportion of patients remained non-
adherent to corticosteroid therapy [7]. Bronchodilators are
predominant medications to treat asthma [8], but contro-
versy exists about the risks and benefits in the application
of bronchodilator drugs, such as long-acting beta-agonists
[9, 10]. Regarding the potential side effects of the long-term
use of conventional drugs, an effective, low-risk, and non-
drug strategy would provide a valuable and adjunctive
treatment in asthma management [11].
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As one of the most important complementary and alter-
native therapies, acupuncture has been used to treat a var-
iety of diseases for more than 2000 years [12]. The WHO
listed asthma and other 42 indications for acupuncture in
1979 [13] and classified the diseases treated by acupunc-
ture into 4 categories, 107 illnesses in 2002, including
asthma [14]. The National Institutes of Health (NIH) rec-
ommended acupuncture as an adjunctive treatment in
comprehensive management programs of addiction, stroke
rehabilitation, asthma, etc. [12, 15]. The British Thoracic
Society suggested that health care professionals should be
aware of the common use of complementary and alterna-
tive medicine in asthma treatment, including acupuncture
[16]. Previous studies suggested that acupuncture was ef-
fective in alleviating asthmatic symptoms and could be
used as an adjunct to the conventional medical manage-
ment of asthma [17]. Acupuncture also improved lung
function and decreased medication dosages [18]. Our pre-
vious clinical study found that acupuncture reduced the
degree and frequency of exacerbations in patients with
asthma [19] and had regulatory effects on mucosal and
cellular immunity in patients with allergic asthma [20].
Despite several published randomized clinical trials
(RCT) evaluating acupuncture as a treatment for asthma,
clear and convincing evidence has not been established
[21, 22]. RCTs of acupuncture in asthma may be limited by
methodological defects such as an inadequate sample size
to meet statistical requirements, poor reporting with miss-
ing information, subjective bias against acupuncture and
improper controls [12, 23, 24]. As a result, a high-quality
RCT assessing the efficacy of acupuncture in the treatment
of asthma is required. This multi-center RCT was designed
to avoid the above-mentioned methodological shortcom-




This RCT will be conducted at 12 clinical centers in
China: Outpatient Department of Shanghai Research Insti-
tute of Acupuncture and Meridian, Long Hua Hospital,
Shu Guang Hospital, Shanghai Hospital of Integrated
Traditional Chinese and Western Medicine, Shanghai First
People’s Hospital, Dachang Hospital, Xiang Ya Hospital,
No. 3 Hospital Affiliated to Henan College of Traditional
Chinese Medicine, Zhengzhou Hospital of Traditional
Chinese Medicine, Kaifeng Hospital of Traditional Chin-
ese Medicine, Wenzhou Hospital of Traditional Chinese
Medicine, Gansu Provincial Hospital of Traditional Chin-
ese Medicine. The acupuncture doctor who treats the pa-
tients, the receptionist who is in charge of the clinical
reception to select eligible patients and randomization,
and assessors who collect data at these 12 clinical centers
must attend a 2-day training seminar prior to the trial to
ensure all practices at each of the 12 clinical centers are
the same. Periodic check-ups contained the coincidence of
the practices taken in every clinical center.
Participants
Recruitment Strategies
There will be two strategies for patient recruitment. Par-
ticipants will be recruited from the outpatient depart-
ments of the 12 clinical centers in China, and printed
recruitment posters will be distributed in public clinics
and nearby communities.
Inclusion criteria
Patients eligible for the trial must comply with all of the
following:
1. Men or women, aged 14–65 years;
2. Patients with asthma history or typical clinical
symptoms;
3. The diagnosis of mild and moderate asthma
according to the Chinese guideline for the
prevention and management of bronchial asthma
[25], with increases in the forced expiratory volume
in 1 second (FEV1) of > 12 % and > 200 mL from
baseline;
4. Agree with all procedures in this trial by signing a
written informed consent form.
Exclusion criteria
Participants meeting any of the following criteria will be
excluded:
1. Participation in another clinical trial in the previous
1 month;
2. Have received systemic corticosteroids in the
previous 2 weeks;
3. With systemic infection, respiratory infection,
pulmonary tuberculosis and fungal infection in the
previous 1 month;
4. Hospitalization due to acute exacerbation of asthma
in the previous 3 months or in the baseline period;
5. Cannot stop using inhaled corticosteroids,
theophylline, long-term β2 agonist, sodium cromo-
glicate, leukotriene antagonists, anticholinergic drugs
or be allergic to albuterol and corticosteroids;
6. Complicated with other severe primary diseases
(including hypertension, cancer, hyperthyroidism,
bronchiectasis, cardiac insufficiency) and conditions
that would prevent participation in the trial or put
the participant at risk;
7. Women who are known to be pregnant or
breastfeeding;
8. Acupuncture contraindications, such as serious
atopic or infectious dermatopathy and hemorrhagic
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diseases (including thrombocytopenic purpura and
hemophilia).
Sample size
Sample size will be based on the primary outcome of the
asthma control test (ACT). According to our pilot study,
we anticipate that the improvement of the ACT will be
3.5 points in the verum acupuncture plus as-needed sal-
butamol aerosol and/or prednisone tablets group and 1.6
points in the sham acupuncture plus as-needed salbuta-
mol aerosol and/or prednisone tablets group. Based on a
0.8 power to detect a significant difference (α = 0.05, 2-
tailed), 86 patients are required for each group with a
1:1 allocation rate. To compensate for dropout patients,
we plan to enroll 100 participants per group, with 200
participants in total.
Ethics and trial registration
This trial is performed according to the principles of the
Declaration of Helsinki. Ethics approval for this study
was granted by the Human Research Ethics Committee
of Yue Yang Hospital of Shanghai University of Trad-
itional Chinese Medicine on 24 June 2013 (Approval
number: 2013–041). The trial was registered on Clinical
Trials.gov on 26 August 2013 (Registration Number:
NCT01931696). Patients must provide written, informed
consent before any study procedures occur.
Procedure
An independent receptionist will initially assess each po-
tential participant according to the inclusion and exclu-
sion criteria. After confirmation of asthma diagnosis,
participants will enter a baseline period of 1 week with-
out treatment, during which they will be trained to use a
peak flow meter, record peak expiratory flow (PEF) and
maintain an asthma diary.
Randomization
After the completion of the baseline evaluation, eligible
participants will be randomly classified into two
groups: the verum acupuncture plus as-needed salbuta-
mol aerosol and/or prednisone tablets group, the sham
acupuncture plus as-needed salbutamol aerosol and/or
prednisone tablets group. A computer-generated, blocked
random allocation sequence will be performed by Drug
And Statistics software 3.2.1 [26]. The receptionist who is
not involved with data collection will provide the random
number and group assignment immediately by using
opaque, sealed envelopes. This procedure guarantees that
randomization concealment is adequate, and will not be
influenced by the acupuncture doctor or participants.
Blinding
In this trial, the receptionist is in charge of clinical recep-
tion and randomization. The acupuncture doctor only
performs the treatment and will not assess the efficacy of
acupuncture. According to the principle of blinding, group
allocation information will be strictly withheld from all pa-
tients. Moreover, the patients, acupuncture doctors, recep-
tionist, assessors and statisticians will be separated and
any communication about the allocation information is
forbidden.
Interventions
Acupuncture will be performed by senior attending doc-
tors at 12 clinical centers. Asthmatic patients randomly
allocated will receive verum/sham acupuncture once
every other day with a total of 20 treatment sessions in 6
weeks and 3 months follow-up (see Fig. 1). Patients are
required to complete case report form (CRF), asthma
quality of life questionnaire (AQLQ) and record daily
asthma symptom scores, acute asthma episodes and the
use of as-needed salbutamol aerosol and/or prednisone
tablets in the asthma diary from the completion of
screening test to the end of the follow-up visits. Salbuta-
mol aerosol (100 μg/puff ) will be taken as needed for
asthma attack. If the symptoms are still not controlled
within a maximum safe dose, prednisone tablets will be
suggested to take at a dose of 20 mg each day for 3–5
days. Patients should record use of salbutamol aerosol
and/or prednisone tablets in the asthma diary.
Verum acupuncture
The acupoints used in the verum acupuncture plus as-
needed salbutamol aerosol and/or prednisone tablets
group are GV14 (Da Zhui), BL12 (Feng Men, bilateral),
BL13 (Fei Shu, bilateral). After the needle insertion, the
de qi sensation will be induced. The twisting and lifting-
thrusting manipulations are performed evenly for 20 sec-
onds every 10 minutes and withdrawn after 30 minutes.
The 0.30 mm (diameter) × 40 mm (length) disposable
needle (Suzhou Medical Appliance Factory, Suzhou,
China) will be used for GV14, and the 0.30 mm (diam-
eter) × 25 mm (length) disposable needle will be used for
bilateral BL12 and BL13.
Sham acupuncture
Inappropriate acupoints for asthma treatment will be
used as the sham acupuncture in the study [27, 28]. To
mimic the acupuncture points in the verum acupuncture
plus as-needed salbutamol aerosol and/or prednisone
tablets group, we choose acupoints DU08 (Jin Suo),
BL18 (Gan Shu, bilateral) and BL19 (Dan Shu, bilateral)
in the sham acupuncture plus as-needed salbutamol
aerosol and/or prednisone tablets group, which is
asthma-irrelevant according to the theory of traditional
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Chinese medicine (TCM). To make the uniform of stimu-
lus quantity, the same manipulation and needles will be
used between the two groups.
Outcome assessments
Primary outcome measurement
The efficacy of acupuncture for chronic asthma is
assessed by the following primary outcome which mea-
sures the change in ACT [29].
Secondary outcome measurements
1. Percentage of symptom-free days (SFDs) [30];
2. Average dosages of salbutamol aerosol and/or
prednisone tablets [31, 32];
3. Lung functions assessed by FEV1 and mean morning
and evening PEF [33, 34];
4. Daily asthma symptom scores [35];
5. AQLQ [36];
6. Peripheral blood eosinophil (EOS) counts;
7. Number of asthma exacerbations.
Follow-up
Follow-up assessments will be conducted at a clinic visit
once every month and last for 3 months. Patients are re-
quired to complete the CRF, AQLQ and assess lung
functions. To encourage participant compliance, we will
show special solicitude for every participant and closely
monitor the evolution of their illness.
Statistical analysis plan
Data integrity
All records will be collected in the original data source.
Primary entries are not allowed to be changed and any
correction should be explained by the responsible acu-
puncture doctor with a signature in the appended notes.
The CRF files will be collected after the verification and
data input will be done separately by two data collectors,
which will be locked once the checking work is done.
Methods of statistical analyses
The modified intent-to-treat (mITT) analysis set will be
considered as the full analysis set. This will include all
evaluable patients: ie, all randomized patients who re-
ceive at least one treatment and who have a score at
randomization and at least one post-randomization ACT
total score. The mITT analysis set will be used for effi-
cacy analyses. Missing data will be replaced according to
the principle of LOCF (the last observation carried for-
ward). The per-protocol (PP) analysis set will include
only those mITT patients who have no significant proto-
col deviations and who received the treatment to which
they were randomized. Analysis of primary efficacy end-
point will be repeated on the PP analysis set to test for
robustness of results. All the randomized patients who
Fig. 1 The flow chart
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receive at least one treatment and for whom any post-
baseline safety data are available will be included in the
safety analysis set. The safety analysis set will be used to
assess safety variables.
In general, all efficacy and safety variables will be sum-
marized using descriptive statistics and graphs as appro-
priate. Continuous variables will be summarized by
descriptive statistics (sample size (n), mean, standard de-
viation (SD), minimum, median and maximum). Cat-
egorical variables will be summarized in frequency tables
(frequencies and percentages). The primary efficacy vari-
able, the change from baseline in ACT total score to the
end of treatment period will be analyzed using an ana-
lysis of covariance (ANCOVA). The ANCOVA analysis
will include the baseline ACT total score as covariate,
treatment as a fixed effect and center as a random effect.
Secondary endpoints will be analyzed using a t test or
Wilcoxon rank sum test as appropriate. All analyses will
be performed using SAS software, version 9.3 (SAS Inc.,
Cary NC, USA). All statistical tests will be conducted at
a 2-tailed significance level of 5 %.
Safety evaluation
Adverse events are defined as unfavorable or unintended
signs, symptoms or diseases occurring after the treat-
ment that are not necessarily related to the acupuncture
intervention. Any adverse event or abnormality will be
recorded in the CRF regardless of relationship to the
study intervention. If any serious adverse events occur,
the intervention will be stopped immediately and appro-
priate action will be taken. This will be reported
promptly to the institutional review board, according to
the protocol.
Discussion
Acupuncture has traditionally been used to treat asthma
in China and has been shown to be beneficial in some as-
pects of asthma [37], but a previous Cochrane review con-
cluded that there was not enough evidence to make
recommendations about the value of acupuncture in
asthma treatment due to poor trial quality, which needed
further research [38]. However, the document of “British
guideline on the management of asthma” explained and
recognized that lack of evidence does not necessarily mean
ineffectiveness of the treatment, which required high-
quality research to support the recommendation [39]. In
this randomized controlled trial, we aim to evaluate the ef-
fect of acupuncture in treating asthma and provide reliable
clinical evidence without bias.
Compared to previous RCTs of acupuncture in treat-
ing asthma [38], the strengths of our trial are that it is
multi-center, with strictly concealed randomization,
rigorous blinding, large sample size, and proper selec-
tion of ACT and AQLQ for evaluating acupuncture
efficacy. The acupoints GV14 (Da Zhui), BL12 (Feng
Men), BL13 (Fei Shu) were selected based on the theory of
TCM and were popularly used in treating asthma in China
[20], which also had supports from our biological studies
[37, 40]. For the sham acupuncture, irrelevant acupoints
were used with the same manipulation as the verum group.
Because Chinese patients are seldom acupuncture-naïve
and most are considerably familiar with acupuncture pro-
cedure and feeling, this means that it is unfeasible to apply
a non-invasive approach. One of the possible limitations in
this trial is the unpredictable stress induced by the sham
acupuncture, which may have certain effect on asthma.
In summary, the efficacy of acupuncture on asthma
will be carefully assessed and the trial aims to provide
reliable clinical evidence for the efficacy of acupuncture
in treating asthma.
Trial status
The trial is currently ongoing. Participant recruitment
started in August 2013, and is expected to end in July 2015.
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